Minoru Kikuoka - Astellas Pharma CFO Officer
| ALPMY Stock | USD 10.09 0.04 0.39% |
Insider
Minoru Kikuoka is CFO Officer of Astellas Pharma
| Phone | 81 3 3244 3000 |
| Web | https://www.astellas.com |
Astellas Pharma Management Efficiency
The company has return on total asset (ROA) of 0.0653 % which means that it generated a profit of $0.0653 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0898 %, meaning that it generated $0.0898 on every $100 dollars invested by stockholders. Astellas Pharma's management efficiency ratios could be used to measure how well Astellas Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Christopher Stevo | Pfizer Inc | N/A | |
| Naoto Tsukaguchi | Daiichi Sankyo | N/A | |
| Tsuyoshi Nakamura | Otsuka Holdings Co | N/A | |
| Bruno Mnard | Sanofi ADR | N/A | |
| Eva SchaeferJansen | Sanofi ADR | N/A | |
| DVM DVM | Pfizer Inc | 60 | |
| Nobue Yasuda | Astellas Pharma | N/A | |
| Junichi Onuma | Daiichi Sankyo | N/A | |
| Makoto Inoue | Otsuka Holdings Co | 65 | |
| Samir MD | Novartis AG ADR | 62 | |
| Sunao DVM | Daiichi Sankyo | 69 | |
| Akio Sakurai | Daiichi Sankyo | N/A | |
| Akiko Ryu | Otsuka Holdings Co | N/A | |
| Karim Mikhail | Amarin PLC | 53 | |
| Paul Penepent | Novartis AG ADR | N/A | |
| Robert Kowalski | Novartis AG ADR | 53 | |
| Patrice Bula | Novartis AG ADR | 65 | |
| Paul Hudson | Sanofi ADR | 57 | |
| Joseph JD | Amarin PLC | 56 | |
| Mike Mcdermott | Pfizer Inc | N/A | |
| Stig Ogata | Astellas Pharma | N/A | |
Management Performance
| Return On Equity | 0.0898 | |||
| Return On Asset | 0.0653 |
Astellas Pharma Leadership Team
Elected by the shareholders, the Astellas Pharma's board of directors comprises two types of representatives: Astellas Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Astellas. The board's role is to monitor Astellas Pharma's management team and ensure that shareholders' interests are well served. Astellas Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Astellas Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Minoru Kikuoka, CFO Officer | ||
| Naoki BSc, Chief VP | ||
| Kenji Yasukawa, Senior Executive Officer, Manager of Vaccine Business Promotion Office | ||
| Stig Ogata, VP Communications | ||
| Chihiro Yokota, Executive Officer, Director of Licensing and Alliance | ||
| Katsuyoshi Sugita, Chief Officer | ||
| Yoshitsugu Shitaka, Executive Officer and Presidentident of Subsidiary | ||
| Nobue Yasuda, Gen Department | ||
| Collette Taylor, VP HR | ||
| Catherine Levitt, G Counsel |
Astellas Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Astellas Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0898 | |||
| Return On Asset | 0.0653 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 26.19 B | |||
| Shares Outstanding | 1.83 B | |||
| Shares Owned By Institutions | 0.03 % | |||
| Price To Earning | 25.98 X | |||
| Price To Book | 2.44 X | |||
| Price To Sales | 0.02 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Astellas Pink Sheet Analysis
When running Astellas Pharma's price analysis, check to measure Astellas Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astellas Pharma is operating at the current time. Most of Astellas Pharma's value examination focuses on studying past and present price action to predict the probability of Astellas Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astellas Pharma's price. Additionally, you may evaluate how the addition of Astellas Pharma to your portfolios can decrease your overall portfolio volatility.